

Lybalvi - (5mg ; Eq 10mg Base,10 mg ; Eq 10 mg Base, 15 mg ; Eq 10 mg Base , 20 mg ; Eq 10mg Base ; Tablet)

Generic Name	Olanzapine; Samidorphan L- Malate	Innovator	Alkermes
Dosage	5mg ; Eq 10mg Base,10 mg ; Eq 10 mg Base, 15 mg ; Eq 10 mg Base , 20 mg ; Eq 10mg Base ; Tablet	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, indicated for the treatment of: • Schizophrenia in adults • Bipolar I disorder in adults o Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate o Maintenance monotherapy treatment		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.